Discussion
The U.S. Food and Drug Administration (FDA) has approved a triple combination of Xpovio (selinexor) plus Velcade (bortezomib) and low-dose dexamethasone for the treatment…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
Discussion
Discussion
A new initiative by GlaxoSmithKline (GSK) is seeking project proposals that will address key needs for people in the multiple myeloma community. Submissions…
Discussion
PF-06863135, a bispecific antibody being developed by Pfizer as an injectable treatment, shows a manageable safety profile and promising response rates at high dose…
Discussion
Ciltacabtagene autoleucel, an investigational CAR T-cell therapy for multiple myeloma, continues to lead to deep and durable responses in heavily treated patients with relapsed or…
Discussion
The Multiple Myeloma Research Foundation (MMRF) has joined forces with the Dana Farber Cancer Institute to develop new biomarkers and treatments for people with smoldering multiple myeloma (SMM) —…
Discussion
Cevostamab (BFCR4350A), a bispecific antibody developed by Roche, induces durable and deep responses in heavily pre-treated patients with relapsed or refractory multiple…
